| Popis: |
Lipa Katarzyna, Jabłońska MagdalenaJulia, Kaczor Patryk, Leis Kamil, Kałużny Krystian, Gałązka Przemysław. Sofosbuvir as a drug in recurrent HCV therapy occurring after liver transplantation. Journal of Education, Health and Sport. 2018;8(9):628-642 eISNN 2391-8306. DOI http://dx.doi.org/10.5281/zenodo.1412333 http://ojs.ukw.edu.pl/index.php/johs/article/view/5950 https://pbn.nauka.gov.pl/sedno-webapp/works/876649 The journal has had 7 points in Ministry of Science and Higher Education parametric evaluation. Part b item 1223 (26/01/2017). 1223 Journal of Education, Health and Sport eissn 2391-8306 7 © The Authors 2018; This article is published with open access at Licensee Open Journal Systems of Kazimierz Wielki University in Bydgoszcz, Poland Open Access. This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author (s) and source are credited. This is an open access article licensed under the terms of the Creative Commons Attribution Non commercial license Share alike. (http://creativecommons.org/licenses/by-nc-sa/4.0/) which permits unrestricted, non commercial use, distribution and reproduction in any medium, provided the work is properly cited. The authors declare that there is no conflict of interests regarding the publication of this paper. Received: 02.08.2018. Revised: 18.08.2018. Accepted: 10.09.2018. Sofosbuvir as a drug in recurrent HCV therapy occurring after liver transplantation Katarzyna Lipa1, Magdalena Julia Jabłońska1, Patryk Kaczor1*, KamilLeis1, Krystian Kałużny2, Przemysław Gałązka3 1Faculty of Medicine, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, 85-067 Bydgoszcz, Poland 2Chair and Clinic of Rehabilitation, Faculty of Health Sciences, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, 85-067 Bydgoszcz, Poland 3Department of General and Oncological Surgery for Children and Adolescents, Antoni Jurasz University Hospital No. 1 in Bydgoszcz, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, 85-094 Bydgoszcz, Poland *Corresponding author: Patryk Kaczor, ul. M. Curie Skłodowskiej 9 85-094 Bydgoszcz, Tel. 52/585 40 15, mail – patryk.kaczor97@gmail.com Abstract Sofosbuvir is a drug, which has been found useful in HCV (Hepatis C Virus) therapy. It replaced the previously used interferon, the applied of which has shown many side effects or lack of response to treatment. The usage of sofosbuvir with ribavirin shortens the time of treatment and minimizes the number of side effects. It is taken as a single dose of 400 mg for 12 or 24 weeks. The only place of activation of this prodrug is hepatocytes, where its active metabolite is formed (GS-461203). It should not be used together with P-glycoprotein inductors that can reduce the efficiency of its action and with amiodarone, because application of both of them together slows down the heart rate. Numerous tests have demonstrated the effectiveness of sofosbuvir in the treatment of patients who have relapsed disease after liver transplantation. A high percentage of sustained virologic response obtained in all phases of clinical trials has proven the efficacy of sofosbuvir in combination with ribavirin or another HCV drug in the therapy of hepatitis C infection. Keywords: sofosbuvir, Hepatis C Virus, liver transplant |
